Wechselwirkungen von Temozolomid
Temozolomid (Temodar) hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 32 dokumentierte Wechselwirkungen: 9 schwerwiegende, 23 mittelschwere, 0 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.
Wechselwirkungen laut Fachinformation
Schwerwiegende Wechselwirkungen (9)
TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (Fachinformation zu Temozolomid, Gegenanzeigen)
- DacarbazinSchwerwiegend
TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (Fachinformation zu Temozolomid, Gegenanzeigen)
TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (Fachinformation zu Temozolomid, Gegenanzeigen)
TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (Fachinformation zu Temozolomid, Gegenanzeigen)
TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (Fachinformation zu Temozolomid, Gegenanzeigen)
TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (Fachinformation zu Temozolomid, Gegenanzeigen)
TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (Fachinformation zu Temozolomid, Gegenanzeigen)
TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (Fachinformation zu Temozolomid, Gegenanzeigen)
TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (Fachinformation zu Temozolomid, Gegenanzeigen)
Mittelschwere Wechselwirkungen (23)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)
Prüfen Sie Temozolomid gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.
Im Wechselwirkungscheck öffnenKeine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.